Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine in Infants

A Randomized Double-Blind Placebo-Controlled Study

Janet A. Englund, MD,* Emmanuel Walter, MD, MPH,† Steven Black, MD,‡ Mark Blatter, MD,§ Jack Nyberg, MS;¶ Frederick L. Ruben, MD,¶ Michael D. Decker, MD, MPH,¶¶ and the GRC28 Study Team

Background: Infants less than 6 months of age are at high risk for influenza disease and influenza-related complications, but no vaccine is licensed for this population.

Methods: A double-blind, randomized, placebo-controlled trial was conducted in 1375 healthy US infants 6 to 12 weeks of age. Subjects received 2 doses of trivalent inactivated influenza vaccine (TIV, Fluzone, sanofi pasteur; N = 915) or placebo (N = 460) 1 month apart in combination with indicated concomitant vaccines. Solicited adverse events were collected for 7 days following vaccination, and unsolicited adverse events for 28 days. Hemagglutination-inhibition antibodies to all 3 vaccine strains were measured following the second TIV/placebo dose.

Results: No significant differences were seen between TIV and placebo groups for any safety outcome. Fever ≥38°C within 3 days of vaccination was seen in 11.2% versus 16.4% in both groups. Reciprocal geometrical mean titer to H1N1, H3N2, and B were 33, 17, and 11 in TIV recipients versus 7, 9, and 5 for placebo recipients. Over 90% of TIV recipients had antibody ≥1.40 for at least 1 vaccine strain and 49.6% for 2 strains, versus 16.4% and 9.9% in placebo-recipients.

Conclusions: TIV administered to young infants beginning at 6 to 12 weeks of age is safe and immunogenic.

Key Words: influenza vaccine, safety, childhood vaccines, safety, immunogenicity (Pediatr Infect Dis J 2010;29: 000–000)
METHODS

Study Design
This was a prospective, multicenter, double-blind, randomized, placebo-controlled trial designed to compare the safety and immunogenicity of a licensed 2005 to 2006 trivalent inactivated influenza vaccine (Fluzone; TIV) to placebo in infants. The study protocol was reviewed by the Food and Drug Administration, and was approved by each institutional review board. Informed consent was obtained from a parent or guardian. Children were randomized 2:1 to receive TIV or placebo using a computer-generated randomization list provided to an interactive voice response system, which was accessed by each site’s study personnel. The investigational vaccine and control product were identical in appearance and labeling, with lot numbers corresponding to the group assignment (investigational or control) assigned to each subject. Study personnel, family, and sanofi pasteur personnel associated with the trial remained blinded throughout the trial.

All children were enrolled at 6 to 12 weeks of age to receive 2 doses of TIV or placebo a month apart (Table 1). Routine childhood vaccines were administered concomitantly with study vaccine at the first visit and without study vaccine at 4 and 6 months of age. Concomitant childhood vaccines were listed in Table, Supplemen- tal Digital Content 1, http://links.lww.com/INF/A222. All vaccines were administered in specified anatomic sites to facilitate reaction assessment, with TIV given in the upper right thigh. Blood was drawn at 4 months of age for determination of influenza antibodies and at 7 months for responses to childhood vaccines.

The primary objective of this study was to demonstrate safety and immunogenicity of 2 doses of TIV administered to infants with concomitant childhood vaccines. We hypothesized that rates of fever ≥38.0°C would be noninferior in children receiving TIV compared with placebo and that antibody responses to TIV would be superior to placebo as measured by the proportion in each group achieving hemagglutination-inhibition titer of ≥1:40 to at least 1 influenza antigen following the second TIV dose.

The estimated projected sample size was 1380 subjects, randomized 2:1 to receive TIV or placebo. Healthy infants were recruited from participating clinics throughout the United States between September 2005 and December 2005. Infants were required to be healthy, 6 to 12 weeks of age at enrollment, born at ≥36 weeks gestation with a birth weight of ≥2.5 kg, and have no egg allergies.

Vaccines
All vaccines except HepB and pneumococcal conjugate vaccine (PNC) were provided by the study sponsor. The 2005 to 2006 pediatric formulation of preservative-free Fluzone TIV (sanofi pasteur, Swiftwater, PA) was used. Each 0.25 mL dose contained 7.5 μg hemagglutinin (HA) of A/New Caledonia/20/99 (H1N1); A/New York/55/2004 (H3N2), and B/Jiangsu/10/2003. The placebo was 0.25 mL sterile with 0.9% sodium chloride. TIV or placebo was administered as a separate intramuscular injection in the right anterolateral thigh using a 25 G, 1.0 inch needle.

Concomitant vaccines are listed in Table 1. The Hib vaccine was given as a separate injection. Vaccination with HepB (provided by each patient’s health care provider) and inactivated polio vaccine (IPV) (IPOL, sanofi pasteur) was permitted at study visits 1 or 2, or at least 7 days apart from study visits 1 or 2.

Safety
Safety outcomes included immediate reactions at the time of vaccination, solicited local and systemic reactions for 7 days, unsolicited adverse events for 28 days, and serious adverse events (SAEs) using previously defined criteria.8,9 Parents maintained a study diary for 7 days. Potentially serious adverse reports were collected through the final parental contact 6 months following the final study visit.

Immunogenicity
Blood samples were obtained at Study Visit 3 and Visit 4. Sera were separated within 2 hours of collection and stored frozen in a monitored freezer at −20°C. Antibody responses to influenza antigens on blood obtained at Study Visit 3 were determined by an HAI performed at sanofi pasteur (Swiftwater, PA) using vaccine antigens provided by Centers for Disease Control.15

Antibody concentrations to other childhood vaccines were obtained from blood obtained at 7 months of age. Pertussis antibody concentrations to 4 antigens were determined by an indirect enzyme-linked immunosorbent assay (ELISA) method. Antidiphtheria antibody responses were measured by Vero cell protection assay and antitetanus titers determined by indirect ELISA, expressed as International Units (IU)/mL compared with World Health Organization standard. Antibody polyribosylribitol phosphate (PRP) concentrations were determined using a Farr-type radioimmunooassay. Type 4, 6B, 9V, 14, 18C, 19F, and 23F pneumococcal antibody concentrations were measured by IgG ELISA and specific poliovirus antibodies by neutralization.

Sample Size and Data Analysis
The planned enrollment of 1380 subjects (randomized 2:1 to receive TIV:placebo) was designed to obtain at least 1200 evaluable subjects, allowing an attrition rate up to 13%. The associated power of this study was 81%, (assuming an incident rate of fever ≥38°C of 10%), to detect a noninferiority criterion of 5%, or

© 2009 Lippincott Williams & Wilkins

Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

TABLE 1. Study Design of Placebo-Controlled Evaluation of Trivalent Inactivated Influenza Vaccine Versus Placebo in Infants Beginning at 2 Months of Age

<table>
<thead>
<tr>
<th>Study Visit 1</th>
<th>Study Visit 2</th>
<th>Study Visit 3</th>
<th>6 mo Vaccinations</th>
<th>Study Visit 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (approx.)</td>
<td>2 mo</td>
<td>3 mo</td>
<td>4 mo</td>
<td>6 mo</td>
</tr>
<tr>
<td>Study vaccines</td>
<td>TIV or Placebo</td>
<td>TIV or Placebo</td>
<td>TIV or Placebo</td>
<td>TIV or Placebo</td>
</tr>
<tr>
<td>Concomitant vaccines</td>
<td>DTaP, Hb, PNC, IPV, HepB*</td>
<td>DTaP, Hb, IPV, PNC; (optionally HepB, IPV)</td>
<td>DTaP, Hb, IPV, PNC; (optionally HepB, IPV)</td>
<td>DTaP, Hb, IPV, PNC; (optionally HepB, IPV)</td>
</tr>
<tr>
<td>Blood drawn</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

*Vaccination with hepatitis B (HepB) and inactivated polio vaccines (IPOL, sanofi pasteur) was permitted during study visits 1 or 2 or any time in-between as long as the vaccination was at least 7 days apart from Study visits 1 and 2.

DTaP indicates diphtheria toxoid-tetanus toxoid-acellular pertussis, (DAPTACE, sanofi pasteur, Swiftwater, PA); Hb, H. influenzae type b conjugate (ActHIB, sanofi pasteur, Swiftwater, PA); IPV, inactivated polio vaccine (IPOL, sanofi pasteur, Swiftwater, PA); PNC, pneumococcal conjugate vaccine, (Prevnar, Wyeth Lederle, Pearl River, NY); HepB, Hepatitis B vaccine.
approximately ruling out a relative risk of $\geq 1.5$-fold increased rate of fever in TIV recipients.

Descriptive and exploratory analyses examined demographic characteristics and frequency and percentage of subjects with local and systemic reactions. The Geometric Mean Titer (GMT) and potential seroprotection rate (proportion of subjects with a postimmunization titer $\geq 1:40$) were determined for each influenza vaccine antigen and 95% confidence intervals (CI) calculated. Seroprotective levels were predefined for antigens in the childhood vaccines: $\geq 0.15$ μg/mL for PRP; $\geq 0.01$ IU/mL for diphtheria and tetanus; $\geq 4$ EU/mL for pertussis toxoid, filamentous hemagglutinin (FIM), and pertactin (PRN); $\geq 1$ EU/mL for filamentous hemagglutinin; $\geq 1:8$ for polioviruses; and $\geq 0.15$ μg/mL for each pneumococcal antigen.

The full data analysis set, considered the “Intention to Treat” (ITT) population, included all randomized subjects who received at least 1 dose of study vaccine/placebo, and had a valid serology result from Visit 3 or 4. The safety analysis included all subjects receiving at least 1 injection of TIV/placebo. Analyses of the primary hypotheses were performed with 2-sided 95% asymptotic CI of the difference in 2 proportions. In the fever analysis, noninferiority of TIV to placebo was established if the upper bound of the 95% CI of TIV minus placebo was below 5%. In the seroprotection primary analysis, superiority of TIV to placebo was established if the lower bound of the 95% CI of TIV minus placebo was above 0. In exploratory analyses, the Pearson $\chi^2$ test was used for categorical data analysis, Student $t$ test for inferential analysis of continuous data, and the log-rank test to analyze the antibody titer reverse cumulative distribution curves (SAS version 8.2, SAS Institute, Cary, NC).

RESULTS

Subjects

A total of 1374 infants were enrolled; 915 were randomized into the TIV group and 459 into the placebo group (Fig., Supplemental Digital Content 2, http://links.lww.com/INF/A223). One subject randomized to receive TIV received 2 doses of placebo, and 1 subject was not randomized but received TIV. Thus, a total of 1375 subjects were analyzed in the Safety Analysis of participants in both groups received 3 doses of Hib, IPV, and pneumococcal conjugate vaccine. Use of antibiotics and antipyretics was similar in both groups.

Safety

Safety profiles were similar in the TIV and placebo groups in terms of immediate adverse events, solicited local and systemic reactions, unsolicited adverse events, and SAEs (Fig. 1). Two subjects in the TIV Group experienced unsolicited adverse events within 20 minutes of vaccination, including one with a nonsevere allergic reaction and other with colic.

Similar proportions of subjects in both groups experienced local injection site reactions within 3 days (Fig. 1), with over 75% of local reactions reported on the day of injection. Most local reactions were mild in intensity and resolved within 2 days. The incidence of local reactions decreased with the second TIV dose (Fig. 1). Similar proportions of subjects in each group (63% in TIV, 65% in placebo group) reported reactions at the DTaP site within 3 days of vaccination.

Fever was the end point for the primary safety hypothesis. The incidence of fever within 3 days was similar in both groups after both doses (Fig. 1). Fever was most commonly reported on the day of injection, but the incidence rapidly decreased such that fever was unusual by day 2 (0.3%–0.7% in each group after either dose). The difference in the group fever rates was $-0.474$ (95% CI, $-4.14–3.20$), satisfying the predefined criteria of noninferiority. The incidence of fever was significantly lower following the second dose of TIV/placebo than following the first dose: 2.3% (19/839, 95% CI: 1.4–3.5) in the TIV group versus 3.8% (16/416, 95% CI: 2.2–6.2) in the placebo group. At postdose 2, an ad hoc noninferiority analysis of TIV versus placebo produced a fever rate difference of $-1.584$ (95% CI: $-3.69–0.52$), achieving the predefined noninferiority criterion.

The percentage of subjects who experienced at least 1 solicited systemic reaction within 3 days of TIV/placebo was 93.4% in the TIV and 92.7% in the placebo group (Table, Supplemental Digital Content 4, http://links.lww.com/INF/A225). No systemic reaction was serious. Rates of solicited systemic reactions within 3 days of Dose 1 and 2 of TIV/placebo were similar in both groups, although higher reaction rates were reported following Dose 1 of TIV, when multiple vaccines were administered.

Unsolicited adverse events (AEs) occurring within 28 days after any study treatment administration were common, but were not significantly different between the 2 groups. Four serious AE’s in TIV recipients lead to study withdrawal: 1 patient developed a hypersensitivity reaction 20 minutes after receiving the first dose of TIV, which was administered simultaneously with DTaP, Hib, and PNC. This urticarial reaction resulted in hives and swelling in 1 ear, requiring treatment with diphenhydramine. The other subjects were withdrawn from the study for unrelated reasons including accidental asphyxiation, urinary tract infection, and formula or milk protein intolerance. The single withdrawal in the placebo group was due to intussusception 118 days postvaccination. Altogether, 1.9% of subjects in the TIV group and 1.5% of subjects in the placebo group experienced a serious adverse event within 28 days. Only 1 of 17 reported SAEs in the TIV group was considered TIV-related, an immediate moderate allergic reaction (described above). Pneumococcal conjugate vaccine (PNC) was the most common SAE reported in both groups, documented in over 50% of all events. The single unrelated death (accidental asphyxiation) occurred 24 days following TIV.

© 2009 Lippincott Williams & Wilkins

www.pidj.com | 3

Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Immunogenicity

Study vaccine immunogenicity is reported for the 1096 subjects in the ITT population. The number of patients who completed the study per protocol and had antibody responses to childhood vaccine antigens included 90.4% of TIV recipients in the ITT population and 88.8% of placebo recipients (Fig. 2). The ITT subjects in the TIV group exhibited statistically superior seroresponse rates to influenza antigens compared with placebo recipients. Overall, 90.2% (671/744) of TIV recipients achieved potential seroprotection (titer ≥1:40) following the second TIV dose to at least one influenza strain compared with 16.4% (57/347) of subjects in the placebo group. The 95% CI of difference in rates between groups (69.3%, 78.2%) easily achieved the superiority criterion of greater than 0.

Seroprotection rates to individual influenza vaccine antigens were significantly higher in the TIV group than the placebo group: 50.1%, 85.6%, and 10.9% for A/New Caledonia/20/99, A/New York/55/2004, and B/Jiangsu/10/2003, respectively, versus 6.9%, 10.1%, 0%

FIGURE 1. Percentage of participants with fever or local reactions (tenderness, redness, or swelling) following first and second doses of TIV/Placebo. No significant differences were noted between TIV and placebo groups at either dose 1 or dose 2 for fever or any local reaction.

FIGURE 2. Immunogenicity of trivalent inactivated influenza vaccine (TIV) versus Placebo groups against the 3 influenza vaccine strains in the intention to treat population. A, Percentage of TIV and placebo recipients with potential seroprotection (titer ≥1:40) after the second dose of TIV/placebo. Responses in TIV group significantly greater than that of placebo group for all 3 antigens, P < 0.001. B, Geometric Mean Titer (GMT) after second dose of TIV or placebo. TIV significantly elevated compared with GMT, P < 0.001.
and 0.3% (P < 0.001). Nearly 50% of infants who received TIV had antibody ≥1:40 for at least 2 vaccine antigens, versus 16.4% and 0.9% in the placebo group, respectively. GMTs were significantly higher for all 3 influenza antigens (P < 0.001 for each strain). The reciprocal GMT for influenza recipients was 33, 95, and 11 for H1N1, H3N2, and B versus 7, 9, and 5 for placebo recipients.

The distribution of antibody titers in infants following the second dose of TIV or placebo is shown in the reverse cumulative distribution curves (Fig., Supplemental Digital Content 5, http://links.lww.com/INF/A226), demonstrating a high percentage of individuals with good antibody responses to influenza A/H1N1 and A/H3N2 and a markedly less robust response to the B antigen (P < 0.001, each strain).

**Concomitant Vaccines**

Administration of TIV at 2 and 3 months of age did not interfere with responses to the concomitant vaccines administered routinely during infancy: post-third-dose antibody responses to all antigens in the DTaP, Hib, IPV, Hep B, and PNC vaccines were not significantly different between the TIV and placebo groups in both the IIT and per-protocol populations. Prespecified seroprotection rates to concomitant vaccine antigens were excellent and uniformly high in both groups. Seroprotection rates in the IIT population to diphtheria, tetanus, PRP, and 3 polioviruses were 100%, 100%, 96.8%, and 100% in the TIV group and 100%, 100%, 96.5, and 100% in the placebo group. Similarly, antibody responses ≥ lower limit of quantitation to pertussis toxoid, filamentous hemagglutinin, PRN, and FIM were between 97% and 100% in subjects in both groups. Responses and GMT to all 7 pneumococcal antigens were likewise very good and similar in both groups (≥99% of subjects with antibody >0.15 μg/mL to serotypes 4, 9V, 14, 18C, and 19F; 94.8% to 98.4% of subjects with antibody >0.15 μg/mL to Serotypes 6B and 23F).

**DISCUSSION**

This study, designed to assess the safety and immunogenicity of TIV in a young population, showed that currently formulated TIV can be administered safely to 6 to 12-week-old infants concomitantly with routine childhood vaccines. TIV was immunogenic in young children and did not inhibit antibody responses to routine vaccines administered concurrently at the first immunization visit. The superiority of TIV to placebo in these infants was demonstrated by higher rates of seroprotection and higher GMTs, a response best illustrated by the reverse cumulative distribution curves for each antigen (Fig., Supplemental Digital Content 5, http://links.lww.com/INF/A226). Results from this study are encouraging for future prospective studies that could evaluate actual efficacy of TIV in young children.

TIV vaccine was well tolerated by infants in this large, placebo-controlled study, again demonstrating the safety of this vaccine in children at all ages.7-10 Specifically, rates of fever following TIV were noninferior to those following placebo after the first dose when multiple childhood immunizations were administered, and after the second dose, when very few concomitant vaccines were given. The higher rate of reactions following the first dose of TIV and placebo is likely related to the administration of multiple concomitant vaccines including PNC at 2 months of age compared with no other vaccine or the relatively nonreactogenic HepB vaccine concurrently with the second dose of TIV/ placebo. Fever following vaccination therefore is more likely attributable to other childhood vaccines rather than TIV. We have previously documented the impact of PNC as a major contributor to fever in young children receiving multiple childhood vaccines including influenza vaccine.8

TIV produced a good immunologic response in young infants vaccinated in the fall during the routine influenza vaccina-

© 2009 Lippincott Williams & Wilkins

**REFERENCES**


